Drug Safety Institute

Drug Safety Institute (DSI), a wholly owned regulatory subsidiary of Brand Institute, was founded in 2004 with the goal of improving the safe use of pharmaceuticals by providing a global, state-of-the-art research model for proprietary (brand name and line extension) and nonproprietary (USAN/INN) pharmaceutical and healthcare nomenclature. Among its many services, DSI offers a medication error prevention analysis associated with labeling of pharmaceuticals, biological products and medical devices, as well various risk management strategies and regulatory submission deliverables.

DSI’s Leadership Team (see below) is comprised of full-time experts who formerly served as key naming, packaging and labeling regulatory officials at FDA, EMA, Health Canada, AMA and WHO. In their former roles, many of our regulatory experts authored the name safety guidance currently in use at their respective agencies. Our DSI Experts have played a key role in making Brand Institute #1 in drug naming worldwide with 14 consecutive years holding a majority global Share of Market Regulatory Name Approvals.

DSI’s methodology for proprietary name safety testing is in full compliance with FDA, EMA, Health Canada, Japan’s Ministry of Health, Labour and Welfare and all other global regulatory agencies for which we provide name safety research.

For immediate regulatory support, contact your local Brand Institute office at the bottom of this page.

Drug Safety Institute is dedicated to improving the safe use of pharmaceuticals by building safety into all of our drug names.

Todd Bridges
Global President, DSI


To provide the global pharmaceutical and biotech communities with regulatory expertise, strategy, and best practices in brand name and nonproprietary (USAN/INN) name development, name safety research, and comprehensive regulatory solutions.

Leadership Team

Todd Bridges

Global President

Mr. Bridges joined DSI – Rockville in May 2018 as Global President. Prior to joining DSI, Mr. Bridges was the Director of the Division of Medication Error Prevention and Analysis (DMEPA) in the Office of Surveillance and Epidemiology at the U.S. Food and Drug Administration (FDA). He has more than thirteen years of DMEPA experience with three of those years as the Director of DMEPA.

As Director of DMEPA, Mr. Bridges was responsible for supervising the premarket review and approval of proposed proprietary/brand drug names, labels/labeling, packaging, product design, United States Adopted Names, biological product proper name suffixes, and human factors studies in order to reduce the potential for medication errors with products regulated by the Center for Drug Evaluation and Research (CDER). DMEPA conducts review and analysis of post-marketing medication errors submitted to CDER to determine if regulatory action such as label/labeling revisions, names change, product redesign, or post-marketing communications to stakeholders is needed. DMEPA also works with external stakeholders, regulators, and researchers to better understand the causes of medication errors and the effectiveness of interventions at preventing them, and provides guidance to the pharmaceutical industry on drug development considerations from a medication errors perspective.

Mr. Bridges has contributed to FDA policy and guidances related to medication errors, represented FDA as a member of the National Coordinating Council for Medication Error Reporting and Prevention as well as the Joint Commission’s Patient Safety Advisory Group, and was responsible for establishing FDA’s ongoing membership with the International Medication Safety Network.

In addition to his FDA experience, Mr. Bridges has thirteen years of pharmacy practice and supervisory experience prior to joining FDA. He has also received specialty training in medication error prevention and analysis from the Institute for Safe Medication Practices.

Mr. Bridges earned his B.S. in Pharmacy from Virginia Commonwealth University’s Medical College.

Sophia Fuerst

President, Nonproprietary Names Division

Ms. Fuerst joined Drug Safety Institute's Nonproprietary (USAN/INN) Names Division as Managing Director in 2005, and was promoted to President in 2007. Ms. Fuerst was formerly Director of the USAN Program at the American Medical Association (AMA) and served in various positions during her 18-year tenure with the Program, including AMA senior staff scientist in the area of Drug Nomenclature.

She was involved in negotiations between the USAN Council, pharmaceutical manufacturers and foreign nomenclature agencies. From 1986 to 2005, Ms. Fuerst was responsible for reviewing submissions, classifying compounds, creating new stems when appropriate and approving and adopting new USAN names.

Ms. Fuerst worked as a consultant, from 1999-2000, to the Secretariat of the INN Programme at the World Health Organization (WHO/INN) in Geneva, Switzerland. Ms. Fuerst holds a B.S. in Biology/Chemistry (pre-med) from St. Joseph's College, an M.S. in Medicinal Chemistry from the University of Chicago and an M.B.A. from Governor's State University in Illinois.

Ioannis (Nakos) Balamotis

President, EU Regulatory Affairs

Dr. Balamotis joined DSI - London as Managing Director, EU Regulatory Affairs in 2014 and in 2018 was promoted to President, EU Regulatory Affairs. Prior to joining DSI, he was a Scientific Administrator for the European Medicine Agency’s (EMA) Name Review Group (NRG).

NRG is responsible for evaluating and approving invented names submitted to the Agency via the centralized procedure. He played an integral role in the development of the EMA’s 2014 NRG Guidelines, which were published in May 2014. Dr. Balamotis reported directly to the EMA’s NRG Secretariat during his tenure with the agency. He participated in all name review meetings and communicated meeting outcomes with NRG affiliates. And, while working on the 2014 guidance document, he liaised with Member States and representatives of the Pharmaceutical Industry, coordinating information and input from all relevant parties. He assisted the EMA in conducting technical reviews of the Product Information (Summary of Product Characteristics, Labeling and Package Leaflets) according to QRD (Quality Review of Documents) standards and in evaluating mock-ups and specimens (packaging artwork). He was also involved in the implementation of the new Pharmacovigilance Legislation, which involved the electronic submission of substance data according to ISO IDMP standards in the first EMA’s electronic medicinal dictionary (XEVMPD).

Dr. Balamotis earned his Doctor of Pharmacy from Carlo Bo University of Urbino, Italy and a B.Sc. in Chemistry at Aristotle University of Thessaloniki, Greece.

Scott Sawler

President, Canadian Regulatory Affairs

Mr. Sawler joined DSI - Ottawa as Managing Director, Canadian Regulatory Affairs in 2017 and in 2018 was promoted to President, Canadian Regulatory Affairs. Prior to joining DSI, he was Director General (DG) of Health Canada’s Marketed Health Products Directorate (MHPD), which is responsible for reviewing and approving proposed proprietary (brand) names; conducting risk/benefit assessments of marketed health products; overseeing the advertising regulatory requirements of health products; providing policies to effectively regulate marketed health products etc.

Among his many roles and accomplishments as DG was leading the development of the 2014 Health Canada Guidance Document for Industry - Review of Brand Names (officially implemented in June of 2015), which provides direction on process and information to be submitted to Health Canada regarding the potential for a proposed name. He also oversaw significant changes to the regulatory framework governing health products were adopted, especially those relating to the Brand Names, Labeling and Packaging of Drugs for Human use. Prior to this, Mr. Sawler was the DG of Health Canada’s Natural and Non-prescription Health Product Directorate where he led the program through a transitional period. He re-established its strategic vision, overhauled its policies and streamlined management systems to put the program back on track. Mr. Sawler also has significant experience as an executive and counsel in clinical trial management, government, legal and regulatory affairs. His clients included pharmaceutical companies, health professional associations, and non-governmental organizations.

Mr. Sawler earned his LL.M. from Osgoode Hall at York University, an M.B.A. from the University of Laval, an LL.B. from the University of Ottawa, and a B.Sc. in Chemistry from the University of New Brunswick.

Nora Roselle

President, U.S. Regulatory Affairs

Dr. Roselle joined DSI - Rockville as Managing Director of U.S. Regulatory Affairs in 2007, promoted in 2012 to Vice President, U.S. Regulatory Affairs and most recently promoted to President, U.S. Regulatory Affairs. Prior to DSI, she served as an officer (LCDR) in the U.S. Public Health Service. She joined the U.S. Food and Drug Administration (FDA) in 2001 as a Safety Evaluator in the Division of Medication Errors and Technical Support (DMETS), in the Office of Drug Safety (ODS), renamed the Office of Surveillance and Epidemiology (OSE), now known as the Division of Medication Error Prevention and Analysis (DMEPA). DMEPA is responsible for the approval of manufacturer’s drug/biologic brand names and human factors/ medication error evaluation of drug and drug/device labeling, packaging, and product design to reduce medication errors.

As Team Leader, Dr. Roselle managed DMETS safety evaluators, proprietary (brand, line extension, and combination product) name reviews, labeling and risk management consults. Dr. Roselle has published several articles on medication errors. Two of her most widely known name safety articles include “Metadate ER or Metadate CD?; Drug Topics 2004,Oct 11:62,64” and “Confusion between Methylphenidate and Methadone, Patient Care 2003, Jan 15:76.” Dr. Roselle earned a Doctor of Pharmacy from the University of Maryland (with Honors) and a B.S. in Biology with a Chemistry Minor from the University of Akron (Cum Laude).

Sandra Van Laan

Senior Vice President, Regulatory Affairs, Nonproprietary Names Division

Ms. Van Laan joined DSI - Chicago in 2006 and is currently the Vice President, Regulatory Affairs, Nonproprietary Division. Prior to joining DSI, she worked for 26 years at the American Medical Association (AMA). Ms. Van Laan was the Associate Secretary to the United States Adopted Names (USAN) Council and a Senior Research Associate at the AMA within the Division of Science and Technology where she provided pharmaceutical expertise to AMA staff for several publications including Current Medical Information and Technology (CMIT), Current Procedural Technology (CPT) and the Journal of the American Medical Association (JAMA). In her role with the USAN Program she provided structural and mechanistic compound analysis to accurately categorize newly submitted names into the appropriate stem classification and shared the responsibility for devising new stems within the taxonomy of nomenclature, when appropriate. The AMA USAN Program is responsible for evaluating and approving nonproprietary names.

She supplied guidance to pharmaceutical companies on the preparation of submissions to the USAN Council and negotiated name candidates with the members of the USAN Council and INN Expert Committee to obtain scientifically appropriate nonproprietary names for worldwide use. Ms. Van Laan has worked closely with the Food and Drug Administration (FDA), Center for Biologics, Evaluation and Research (CBER), and the United States Pharmacopeial (USP) Convention for the standardization of nonproprietary nomenclature and has participated in regulatory strategic planning sessions and intellectual property protection discussions pertaining to nonproprietary names. Ms. Van Laan authored the pronunciation guidelines for nonproprietary names that are the industry standard today.

José-Ángel Ferrero

Vice President, EU Regulatory Affairs & Safety Research

Dr. Ferrero joined DSI - London in 2017 as Drug Safety Institute - Vice President, EU Regulatory Affairs & Safety Research. Prior to joining DSI, he was a Labeling Specialist and Scientific Administrator of the Name Review Group (NRG) – European Medicines Agency (EMA) for over 5 years, the group that is responsible for evaluating and approving invented (brand) names submitted to the Agency via the centralized procedure. In his role at EMA, he was responsible for the drafting and handling of revision 6 of the 2014 “Guideline on the acceptability of names for medicinal products processed through the centralized procedure.”

Dr. Ferrero managed all aspects related to the activities and work of the NRG, including the preparation of NRG meetings, support to the NRG Chair before, during and following NRG meetings, preparation of agendas and minutes, preparation of all internal/external correspondence and preparation of reports/memos on NRG related Member States correspondence for invented name submissions, reviews and approvals. He proposed and developed a decision tool for the evaluation/discussion of objections due to orthographic and phonetic similarity. This tool has led to a consistent approach to the discussion of objections with the NRG and was integrated in EMA’s name review process in 2015. As labelling specialist, he was responsible for the management of the labelling review and Quality Review of Documents (QRD) standards’ check of Summaries of Product Characteristics, Labelling and Package Leaflet for assigned product portfolio. He also drafted the EMA’s policy “Quick Response (QR) codes in the labeling and package leaflet of centrally authorized medicinal products.”

He earned his post-graduate Pharm.D. degree in Clinical Pharmacy (secondary care) from the University of Bradford, UK and his BSc in Pharmacy from the University of Salamanca, Spain. Prior to joining EMA, he accomplished senior clinical pharmacist roles at Sheffield Teaching Hospitals, UK.

Baptiste Lacoustille

Pharm.D., M.S. - Drug Safety Evaluator

Dr. Lacoustille joined BI - Basel as Vice President, Brand Development in 2017 and joined our subsidiary, Drug Safety Institute, as Drug Safety Evaluator in 2019. Prior to joining BI, he worked in the Labeling Review and Standards Office at the European Medicines Agency (EMA) in London, UK. In this role Baptiste participated in Name Review Group (NRG) meetings, and was responsible for researching, analyzing and preparing for the review and acceptability of invented names for medicinal products according to the EMA 2014 NRG Guidelines. Baptiste reported directly to the NRG Chairperson,the head of the division responsible for evaluating and approving invented names submitted to the agency via the centralized procedure.

Dr. Lacoustille’s additional responsibilities at the EMA included reviewing the quality of product information (SmPC, package leaflet, labeling) according to QRD (QualityReview of Documents) standards for centrally authorized medicines in different therapeutic areas. He was appointed “Labeling Specialist” for the Imm suppressants Product Portfolio where he served as an integral member of an “EMA Product Team” made up of various experts, providing labeling advice to pharmaceutical companies at pre-submission, assessment and post-authorization stages. Prior to his time at the EMA, he served in Regulatory Affairs at GlaxoSmithKline and in regulatory compliance at LFB Biomédicaments.

He earned his Pharm.D. and M.S. in International Regulatory Environment of Healthcare Industries and Health Products from Montpellier University.